Format

Send to

Choose Destination
Drug Metab Lett. 2007 Apr;1(2):153-61.

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.

Author information

1
Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. punam_sandhu@merck.com

Abstract

The disposition of vorinostat, an anticancer agent, was investigated in rats and dogs. Vorinostat possessed high serum clearance, a short elimination half-life and low oral bioavailability in both species. The renal route played an important role in the elimination of drug-related material and vorinostat was eliminated primarily by metabolic biotransformation.

PMID:
19356036
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center